Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocular Therapeutix Inc OCUL

Healthcare
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular... see more

Recent & Breaking News (NDAQ:OCUL)

Ocular Therapeutix(TM) to Present at the 17th Annual BIO CEO & Investor Conference

Business Wire February 4, 2015

Ocular Therapeutix(TM) Enrolls First Patient in Phase 2 Clinical Trial for Sustained Release Dexamethasone for the Treatment of Dry Eye Disease

Business Wire January 21, 2015

Ocular Therapeutix(TM) to Present at Oppenheimer 25th Annual Healthcare Conference

Business Wire December 2, 2014

Ora-CAC® Model Provided Platform for Recent Positive Phase 2 Data for Ocular Therapeutix's OTX-DP in Allergic Conjunctivitis

Business Wire November 24, 2014

Ocular Therapeutix(TM) Reports Third Quarter 2014 Financial Results

Business Wire November 12, 2014

Ocular Therapeutix(TM) Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release Travoprost for the Treatment of Glaucoma and Ocular Hypertension

Business Wire November 12, 2014

Ocular Therapeutix(TM) Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis

Business Wire November 12, 2014

Ocular Therapeutix(TM) to Report Third Quarter 2014 Financial Results and Provide Business Updates on Wednesday, November 12, 2014

Business Wire November 5, 2014

Ocular Therapeutix(TM) to Participate in Two Investor Conferences in November 2014

Business Wire October 31, 2014

Ocular Therapeutix(TM) to Attend American Academy of Ophthalmology Annual Meeting in Chicago, Illinois

Business Wire October 14, 2014

Ocular Therapeutix(TM) Completes Enrollment in Phase 3 Sustained Release Dexamethasone Trials for Post-Operative Inflammation and Pain

Business Wire October 8, 2014

Ocular Therapeutix to Present at the 21st Annual NewsMakers in the Biotech Industry Investment Conference on Friday, September 26

Business Wire September 16, 2014

Ocular Therapeutix to Present at Morgan Stanley 2014 Global Healthcare Conference

Business Wire September 3, 2014

Ocular Therapeutix Announces Second Quarter 2014 Financial Results

Business Wire August 28, 2014

Ocular Therapeutix Announces Exercise of Over-Allotment Option

Business Wire August 19, 2014

Ocular Therapeutix (NASDAQ: OCUL) to Ring The NASDAQ Stock Market Closing Bell

GlobeNewswire July 31, 2014

Ocular Therapeutix Announces Closing of Initial Public Offering

Business Wire July 30, 2014

Ocular Therapeutix Prices Initial Public Offering

Business Wire July 24, 2014